Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Coagulation

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

Leitlinie der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) zur Struktur- und Prozessqualität von Hämophilie-Zentren.

Hamostaseologie·2024

Same author

Fibrinogen Bonn (p. Arg510Cys) in the Aα-Chain Is Associated with High Risk of Venous Thrombosis.

Hamostaseologie·2023

Same author

Experiences in Routine Genetic Analysis of Hereditary Hemorrhagic, Thrombotic, and Platelet Disorders.

Hamostaseologie·2022

Same author

Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.

ESMO open·2021

Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026

Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

Same journal

Hamostaseologie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

[Clotting factor concentrates].

M Barthels¹, J Oldenburg

¹Abteilung Hämatologie, Hämostaseologie und Onkologie, Medizinische Hochschule Hannover. mbarthels.hannover@gmx.de

Hamostaseologie

|January 10, 2009

Summary

This summary is machine-generated.

This survey reviews plasma-derived and recombinant coagulation factor concentrates. Careful consideration of effectiveness versus side effects is crucial for patient treatment.

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Related Experiment Videos

Last Updated: Jun 26, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Area of Science:

Hematology
Pharmacology

Context:

Coagulation factor concentrates are vital for treating bleeding disorders.
Both plasma-derived and recombinant factors are used in substitution therapy.

Purpose:

To survey the indications and clinical use of plasma-derived and recombinant coagulation factor concentrates.
To highlight the importance of balancing treatment efficacy with potential adverse effects.

Summary:

This review covers the applications of plasma-derived and recombinant coagulation factor concentrates.
It emphasizes the need for careful patient management, considering both therapeutic benefits and risks.
Long-term and short-term side effects must be weighed against treatment effectiveness.

Impact:

Provides a comprehensive overview for clinicians managing patients requiring coagulation factor replacement.
Informs therapeutic decisions by detailing the risk-benefit profile of different factor concentrates.
Contributes to optimizing patient care in hemophilia and other coagulation factor deficiencies.